Skip to main content

Table 1 Molecular targets of the kinase inhibitors and antibodies mentioned in text

From: Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

TKI/Ab

RET

BRAF

RAF-1

mTOR

cMET

c-Kit

VEGFR1

VEGFR2

VEGFR3

PDGFRα

PDGFRβ

EGFR

MEK

BCR/ABL

NTRK

Axitinib

      

x

x

x

      

Imatinib

x

    

x

   

x

x

  

x

 

Sorafenib

 

x

x

    

x

x

 

x

    

Sunitinib

x

    

x

x

x

x

x

x

    

Pazopanib

     

x

x

x

x

x

x

    

Vandetanib

x

      

x

x

  

x

   

Erlotinib

           

x

   

Gefitinib

           

x

   

Dabrafenib

 

xa

             

Vemurafenib

 

xa

             

Cobimetinib

            

x

  

Trametinib

            

x

  

Everolimus

   

x

           

Cetuximab

           

x

   

Bevacizumab

      

x

x

       

Lenvatinib

x

    

x

x

x

x

x

     

Larotrectinib

              

x

  1. TKI Tyrosine kinase inhibitor, Ab Antibody
  2. aMutant BRAF(V600E)
Back to article page

Thyroid Research

ISSN: 1756-6614